---
title: Mutational profile of previously treated chronic lymphocytic leukemia patients
  progressing on acalabrutinib or ibrutinib
date: '2024-05-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38754046/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240517181948&v=2.18.0.post9+e462414
source: Blood
description: Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine
  kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor
  pathway mutations. Using peripheral blood samples from relapsed/refractory CLL patients
  in ELEVATE-RR (NCT02477696) (median 2 prior therapies), we report clonal evolution
  data for patients progressing on acalabrutinib or ibrutinib (median follow-up 41
  months). Paired (baseline and progression) samples were available for 47 (excluding
  ...
disable_comments: true
---
Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations. Using peripheral blood samples from relapsed/refractory CLL patients in ELEVATE-RR (NCT02477696) (median 2 prior therapies), we report clonal evolution data for patients progressing on acalabrutinib or ibrutinib (median follow-up 41 months). Paired (baseline and progression) samples were available for 47 (excluding ...